167 related articles for article (PubMed ID: 35273728)
1. NY-ESO-1 as a diagnostic and prognostic marker for myxoid liposarcoma.
Jo U; Roh J; Song MJ; Cho KJ; Kim W; Song JS
Am J Transl Res; 2022; 14(2):1268-1278. PubMed ID: 35273728
[TBL] [Abstract][Full Text] [Related]
2. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.
Hemminger JA; Iwenofu OH
Mod Pathol; 2013 Sep; 26(9):1204-10. PubMed ID: 23599152
[TBL] [Abstract][Full Text] [Related]
3. [Pathological significance of NY-ESO-1 expression in the diagnosis of myxoid liposarcoma].
Hei SM; Wei HJ; Chen H; Wang JG
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):225-230. PubMed ID: 30831650
[No Abstract] [Full Text] [Related]
4. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.
Iura K; Kohashi K; Hotokebuchi Y; Ishii T; Maekawa A; Yamada Y; Yamamoto H; Iwamoto Y; Oda Y
J Pathol Clin Res; 2015 Jul; 1(3):144-59. PubMed ID: 27499900
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.
Kakimoto T; Matsumine A; Kageyama S; Asanuma K; Matsubara T; Nakamura T; Iino T; Ikeda H; Shiku H; Sudo A
Oncol Lett; 2019 Apr; 17(4):3937-3943. PubMed ID: 30881511
[TBL] [Abstract][Full Text] [Related]
6. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
Pollack SM; Jungbluth AA; Hoch BL; Farrar EA; Bleakley M; Schneider DJ; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
Cancer; 2012 Sep; 118(18):4564-70. PubMed ID: 22359263
[TBL] [Abstract][Full Text] [Related]
7. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.
Hemminger JA; Ewart Toland A; Scharschmidt TJ; Mayerson JL; Kraybill WG; Guttridge DC; Iwenofu OH
Mod Pathol; 2013 Feb; 26(2):282-8. PubMed ID: 22936067
[TBL] [Abstract][Full Text] [Related]
8. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.
Iura K; Kohashi K; Ishii T; Maekawa A; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Matsumoto Y; Iwamoto Y; Oda Y
Virchows Arch; 2017 Sep; 471(3):383-392. PubMed ID: 28744588
[TBL] [Abstract][Full Text] [Related]
9. The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.
Pollack SM
Expert Rev Vaccines; 2018 Feb; 17(2):107-114. PubMed ID: 29280411
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
[TBL] [Abstract][Full Text] [Related]
11. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
12. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.
Endo M; de Graaff MA; Ingram DR; Lim S; Lev DC; Briaire-de Bruijn IH; Somaiah N; Bovée JV; Lazar AJ; Nielsen TO
Mod Pathol; 2015 Apr; 28(4):587-95. PubMed ID: 25412843
[TBL] [Abstract][Full Text] [Related]
13. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological Assessment of Cancer/Testis Antigens NY-ESO-1 and MAGE-A4 in Highly Aggressive Soft Tissue Sarcomas.
Hashimoto K; Nishimura S; Ito T; Akagi M
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328286
[TBL] [Abstract][Full Text] [Related]
15. Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.
Chawla SP; Van Tine BA; Pollack SM; Ganjoo KN; Elias AD; Riedel RF; Attia S; Choy E; Okuno SH; Agulnik M; von Mehren M; Livingston MB; Keedy VL; Verschraegen CF; Philip T; Bohac GC; Yurasov S; Yakovich A; Lu H; Chen M; Maki RG
J Clin Oncol; 2022 Apr; 40(12):1291-1300. PubMed ID: 34260265
[TBL] [Abstract][Full Text] [Related]
16. The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study.
Wang YX; Li FL; Du LX; Liu JF; Huo LG; Li SQ; Tian B
Cancer Manag Res; 2021; 13():6123-6128. PubMed ID: 34377031
[TBL] [Abstract][Full Text] [Related]
17. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma.
Gjerstorff MF; Pøhl M; Olsen KE; Ditzel HJ
BMC Cancer; 2013 Oct; 13():466. PubMed ID: 24103781
[TBL] [Abstract][Full Text] [Related]
18. Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors.
Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Kakinoki R; Akagi M
Medicine (Baltimore); 2023 Jun; 102(22):e33908. PubMed ID: 37266606
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma.
Ries J; Mollaoglu N; Vairaktaris E; Neukam FW; Nkenke E
Anticancer Res; 2009 Dec; 29(12):5125-30. PubMed ID: 20044626
[TBL] [Abstract][Full Text] [Related]
20. Myxoid liposarcoma with nuclear pleomorphism: a clinicopathological and molecular study.
Kojima N; Kubo T; Mori T; Satomi K; Matsushita Y; Iwata S; Yatabe Y; Ichimura K; Kawai A; Ichikawa H; Yoshida A
Virchows Arch; 2024 Jan; 484(1):71-81. PubMed ID: 37704823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
